215 related articles for article (PubMed ID: 25423927)
1. [New Developments in CKD-MBD. New aspects in phosphate binders].
Yokoyama K
Clin Calcium; 2014 Dec; 24(12):1815-23. PubMed ID: 25423927
[TBL] [Abstract][Full Text] [Related]
2. [New Developments in CKD-MBD. Future perspective of calcimimetics].
Mizobuchi M; Inoue T
Clin Calcium; 2014 Dec; 24(12):1825-30. PubMed ID: 25423928
[TBL] [Abstract][Full Text] [Related]
3. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Hanafusa N
Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
5. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
6. CKD-MBD: impact on management of kidney disease.
Ogata H; Koiwa F; Kinugasa E; Akizawa T
Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
[TBL] [Abstract][Full Text] [Related]
7. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
Oliveira RB; Cancela AL; Graciolli FG; Dos Reis LM; Draibe SA; Cuppari L; Carvalho AB; Jorgetti V; Canziani ME; Moysés RM
Clin J Am Soc Nephrol; 2010 Feb; 5(2):286-91. PubMed ID: 19965540
[TBL] [Abstract][Full Text] [Related]
8. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
9. Effects of phosphate binders in moderate CKD.
Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
[TBL] [Abstract][Full Text] [Related]
10. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
Wesseling-Perry K; Salusky IB
Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
[TBL] [Abstract][Full Text] [Related]
11. The future of phosphate binders: a perspective on novel therapeutics.
Cernaro V; Santoro D; Lucisano S; Nicocia G; Lacquaniti A; Buemi M
Expert Opin Investig Drugs; 2014 Nov; 23(11):1459-63. PubMed ID: 25243756
[TBL] [Abstract][Full Text] [Related]
12. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
13. Osteo-renal regulation of systemic phosphate metabolism.
Razzaque MS
IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Cozzolino M; Brancaccio D
Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
[TBL] [Abstract][Full Text] [Related]
15. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
16. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
[TBL] [Abstract][Full Text] [Related]
18. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
[TBL] [Abstract][Full Text] [Related]
19. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
Cozzolino M; Bruschetta E; Cusi D; Montanari E; Giovenzana ME; Galassi A
Expert Opin Pharmacother; 2012 Nov; 13(16):2337-53. PubMed ID: 23033914
[TBL] [Abstract][Full Text] [Related]
20. [New Developments in CKD-MBD. Strategies for the management of predilalysis CKD-MBD].
Ando R
Clin Calcium; 2014 Dec; 24(12):1845-51. PubMed ID: 25423931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
